Washington, D.C. (March 9, 2016) – Biotechnology Innovation Organization (BIO) President and CEO Jim Greenwood released the following statement regarding today’s Senate HELP Committee mark-up of legislation as part of the Senate biomedical innovation initiative:
“BIO applauds today’s bipartisan votes by the Senate HELP Committee to advance legislation as part of the Senate biomedical innovation initiative. In particular, BIO applauds the Committee’s passage of The Advancing Hope Act of 2015, reauthorizing the Pediatric Rare Disease Priority Review Voucher Program, which provides an important incentive for companies developing treatments for rare pediatric diseases. We were also pleased that the Committee passed legislation to add the Zika virus to the Tropical Disease Priority Review Voucher program.
“BIO was very encouraged that the Committee passed the Medical Countermeasures Innovation Act of 2015, addressing a number of contracting and regulatory challenges and incentivizing further research and development of critical medical countermeasures products.
“BIO and our members have been engaged throughout this bipartisan process, and we look forward to working with members of the Committee on common sense reforms that will improve the entire ecosystem of innovation which patients rely upon to deliver new treatments. We thank Chairman Alexander, Ranking Member Murray and all members of the Committee for their commitment to this important work.”
Upcoming BIO Events
BIO International Convention |
|
13th Annual BIO Asia International Conference | BIO-Europe Spring |
